Journal
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Volume 112, Issue 45, Pages 14078-14083Publisher
NATL ACAD SCIENCES
DOI: 10.1073/pnas.1512812112
Keywords
neurodegenerative; basal ganglia; movement disorder; trinucleotide repeat disorder
Categories
Funding
- National Institutes of Health [U01MH067965]
- National Institute of Neurological Disorders and Stroke [R01 NS065867]
- National Institute of Mental Health [5P56-NS071669]
- NIH/National Institute of Environmental Health Sciences [R01 ES016931]
Ask authors/readers for more resources
Mutations that lead to Huntington's disease (HD) result in increased transmission at glutamatergic corticostriatal synapses at early pre-symptomatic stages that have been postulated to set the stage for pathological changes and symptoms that are observed at later ages. Based on this, pharmacological interventions that reverse excessive corticostriatal transmission may provide a novel approach for reducing early physiological changes and motor symptoms observed in HD. We report that activation of the M-4 subtype of muscarinic acetylcholine receptor reduces transmission at corticostriatal synapses and that this effect is dramatically enhanced in presymptomatic YAC128 HD and BACHD relative to wild-type mice. Furthermore, chronic administration of a novel highly selective M-4 positive allosteric modulator (PAM) beginning at presymptomatic ages improves motor and synaptic deficits in 5-mo-old YAC128 mice. These data raise the exciting possibility that selective M-4 PAMs could provide a therapeutic strategy for the treatment of HD.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available